Maxigesic IV: The Unique Blend of Paracetamol and Ibuprofen in Pain Control
Introduction
Pain management is a critical aspect of healthcare, particularly in the context of post-operative recovery. Traditionally, opioid medications have been the go-to solution for pain relief, but the opioid crisis has shed light on the need for effective non-opioid alternatives.
In response to this pressing issue, Hyloris Pharmaceuticals SA, a Belgium-based specialty biopharma company, has developed combination of paracetamol and ibuprufen in intravenous formulation, a groundbreaking medication that combines the well-known pain relievers paracetamol (acetaminophen) and ibuprofen in an intravenous formulation.
The Need for Non-Opioid Solutions
Post-operative pain is an inevitable consequence of surgical procedures, and its effective management is crucial for patients’ comfort and recovery. For years, opioid-based medications have been the primary means of pain relief in post-operative settings. However, the alarming rise of the opioid crisis in the United States, characterized by its devastating impact, has created a pressing need for non-opioid alternatives.
Chronic opioid use following surgery has become one of the most common complications, contributing significantly to th opoid epidemic in the USA ,the consequences are dire, with over 600,000 opioid-related deaths in the United States over the past two decades.
- Opioid Overdose Deaths:
- Almost 50,000 people die every year from opioid overdose.
- Opioid Misuse:
- Over 10 million people misuse opioids in a year.
- Opioid Overdose Contribution:
- Opioids are a factor in at least 7 out of every 10 overdose deaths.
In 2021, opioid overdoses claimed approximately 80,000 lives, with prescription opioids playing a substantial role. The cost to the healthcare system is immense, with patients requiring medical attention for opioid abuse adding around $11 billion in expenses annually, representing 1% of all hospital costs.
The opioid crisis has ignited a collective awareness of the societal impact of opioid abuse, prompting a decline in opioid prescriptions over the past decade. This reduction underscores the necessity for potent, non-opioid alternatives that can provide effective pain relief without the associated risks.
Maxigesic® IV: A Unique Blend
Maxigesic IV, developed by Hyloris Pharmaceuticals SA, offers a groundbreaking solution to the challenges of post-operative pain management. It combines two widely recognized pain relievers, paracetamol and ibuprofen, in an intravenous formulation. The combination of these two active ingredients is what sets Maxigesic IV apart.
Paracetamol is renowned for its effectiveness in reducing fever and providing relief from mild to moderate pain. Ibuprofen, on the other hand, is a nonsteroidal anti-inflammatory drug (NSAID) known for its ability to alleviate pain and inflammation.
When administered intravenously, the synergy of these two active ingredients results in a more potent and faster-acting pain relief option than when used individually.
Hyloris Pharmaceuticals SA: A Foreign Innovator
Hyloris Pharmaceuticals SA is a specialty biopharma company based in Liège, Belgium. The company is committed to addressing unmet medical needs by reinventing existing medications and delivering relevant improvements for patients, healthcare professionals, and payors.
Hyloris has developed a portfolio of reformulated and repurposed medicines, with Maxigesic IV standing as a testament to their dedication to innovation in pain management.
Bottom line
Maxigesic IV represents a remarkable step forward in post-operative pain management, offering a potent non-opioid alternative that is well-tolerated, provides faster relief, and reduces opioid consumption. Maxigesic IV promises to make a significant impact in addressing the opioid crisis in the United States.
As healthcare professionals and patients increasingly seek safer and more effective pain management options, Maxigesic IV stands out as a groundbreaking solution that holds the promise of improving patient outcomes and reducing the societal impact of opioid abuse, all while originating from a foreign-based company.
Note for the USA citizen
FDA approval
The FDA approval status for Maxigesic® IV cannot be found on the FDA website.
